NASDAQ:PFSA Profusa Q3 2025 Earnings Results & Report $1.42 -0.07 (-4.70%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.48 +0.06 (+3.87%) As of 10/9/2026 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Profusa reported Q3 2025 earnings on November 19, 2025. The company reported EPS of -$5,250.00. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 19, 2025TimeAfter Market Closes Profusa EPS ResultsActual EPS-$5,250.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AProfusa Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Profusa Q3 2025 Earnings FAQ Did Profusa beat earnings estimates for Q3 2025? Profusa (NASDAQ:PFSA) reported earnings of -$5,250.00 per share for Q3 2025. The report was announced on Wednesday, November 19, 2025. Profusa Earnings HeadlinesProfusa Announces Significant Progress towards Lumee Oxygen Platform CE Mark with ISO 13485 certification Expected in Early OctoberSeptember 25, 2026 | marketscreener.comMHere’s What Investors Are Watching, Including $20 Price Target BombshellSeptember 24, 2026 | markets.businessinsider.comTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.October 10 at 1:00 AM | Banyan Hill Publishing (Ad)Profusa ISO 13485 certification decision advances Lumee oxygen platform toward CE markSeptember 24, 2026 | msn.comMicro Cap Profusa Navigates European Regulatory Hurdles to Advance Oxygen Monitoring TechSeptember 24, 2026 | benzinga.comProfusa Advances Lumee Oxygen Platform Toward CE MarkSeptember 24, 2026 | rttnews.comSee More Profusa Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Profusa? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Profusa and other key companies, straight to your email. Email Address About ProfusaProfusa (NASDAQ:PFSA) is a biotechnology company developing implantable biosensor technology designed to continuously monitor body chemistry. Its sensors are engineered to integrate with tissue and detect selected biological signals, with the goal of providing real-time health data through an external reader or connected digital device. The company’s technology platform has been studied for applications including monitoring oxygen and other biomarkers that may assist with disease management, clinical research, and personalized healthcare. Profusa has also developed the Lumee oxygen-sensing system and has explored additional uses for its biosensors in areas such as chronic-condition monitoring and remote patient care. Profusa’s work has included collaborations and research programs involving government and healthcare organizations. The company’s technology remains focused on developing less invasive, continuous monitoring solutions that could complement conventional laboratory testing and periodic measurements.View Profusa ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
